Trial Profile
A Dose Block-randomized, Double-blind, Placebo-controlled, Single/Multiple Dosing, Dose Escalation Clinical Phase 1 Study to Investigate the Safety, Tolerance, and Pharmacokinetics/Pharmacodynamics of DA-1229 in Healthy Male Subjects
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Evogliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Dong-A Pharmaceutical
- 27 Aug 2009 New trial record